Biomarin Pharmaceutical (NASDAQ:BMRN) just reported results for the second quarter of 2024.
- Biomarin Pharmaceutical reported earnings per share of 96 cents. This was above the analyst estimate for EPS of 35 cents.
- The company reported revenue of $712.03 million.
- This was 7.68% better than the analyst estimate for revenue of $661.23 million.